Residency · Residency · Hematology Thrombosis

Venous Thromboembolism - DVT and PE Management

Introduction

Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disease after myocardial infarction and stroke, with an annual incidence of approximately 1 to 2 per 1,000 individuals in the general population. The clinical significance of VTE extends well beyond the acute event: 30-day mortality rates are approximately 5% for DVT and 10 to 15% for PE, rising to 30 to 50% for massive PE presenting with hemodynamic collapse. Among survivors, the risk of recurrence is substantial, estimated at approximately 30% over 10 years for patients with unprovoked VTE who do not receive extended anticoagulation. These statistics underscore the importance of accurate risk stratification, evidence-based treatment, and individualized decisions regarding the duration of anticoagulant therapy.

Risk Factors (Virchow Triad)

The pathogenesis of VTE is classically understood through Virchow's triad, which identifies three broad categories of predisposing factors: venous stasis, endothelial injury, and hypercoagulability. In most patients who develop VTE, multiple elements of the triad operate simultaneously.

Stasis

Venous stasis is among the most potent risk factors for VTE and underlies the well-established association between VTE and immobilization, major surgery (particularly orthopedic procedures involving the lower extremities), long-haul air travel, paralysis from stroke or spinal cord injury, and congestive heart failure. Obesity has emerged as a major independent risk factor for VTE, with a body mass index above 30 conferring an odds ratio of 2 to 3 for VTE, mediated in part by impaired venous return from the lower extremities and in part by the prothrombotic inflammatory milieu associated with adipose tissue.

Endothelial Injury

Direct injury to the venous endothelium disrupts the normal antithrombotic surface and exposes subendothelial tissue factor and collagen. Major surgery, trauma, central venous catheter placement, and prior DVT with residual vein damage are the most common causes. The combination of endothelial injury with stasis during the postoperative period explains the particularly high incidence of VTE following major surgical procedures.

Hypercoagulability

Hypercoagulable states may be acquired or inherited and are discussed in detail in the lecture on thrombophilia evaluation. Among acquired hypercoagulable conditions, malignancy is the most potent, conferring a 4- to 7-fold increase in VTE risk through mechanisms including tumor-derived tissue factor, mucin-mediated platelet activation, and chemotherapy-induced endothelial damage. Other important acquired risk factors include pregnancy and the postpartum period, hormonal therapy (oral contraceptives and hormone replacement therapy), antiphospholipid syndrome, myeloproliferative neoplasms, nephrotic syndrome (loss of antithrombin and other anticoagulant proteins), and inflammatory bowel disease. Inherited thrombophilias, including factor V Leiden, prothrombin G20210A mutation, and deficiencies of antithrombin, protein C, or protein S, are discussed in detail in Lecture 28.

Provoked vs. Unprovoked VTE

The distinction between provoked and unprovoked VTE is the single most important determinant of anticoagulation duration and recurrence risk. VTE provoked by a major transient risk factor, defined as surgery with general anesthesia lasting more than 30 minutes, major trauma, or immobilization for 3 or more days within the preceding 3 months, carries a low recurrence risk after a standard course of anticoagulation and generally requires only 3 months of treatment. VTE provoked by a minor transient risk factor, such as hospitalization for less than 3 days, estrogen therapy, pregnancy, leg injury with limited mobility, or prolonged travel exceeding 8 hours, carries an intermediate recurrence risk. Unprovoked or idiopathic VTE, occurring in the absence of any identifiable provoking factor, carries a high recurrence risk estimated at 8 to 10% per year after discontinuation of anticoagulation, and is the clinical scenario in which extended or indefinite anticoagulation should be strongly considered. Cancer-associated VTE carries the highest recurrence risk of all and requires extended anticoagulation for as long as the malignancy remains active or the patient continues to receive cancer-directed therapy.

Diagnosis

DVT Diagnosis

The diagnostic approach to suspected DVT integrates clinical probability assessment, D-dimer testing, and imaging in a validated sequential algorithm designed to minimize both missed diagnoses and unnecessary testing. Clinical assessment begins with the Wells score for DVT, which assigns points based on the presence of active cancer, paralysis or recent immobilization, recent bedridden status or surgery, tenderness along the deep venous system, entire leg swelling, calf swelling exceeding 3 cm compared to the asymptomatic side, pitting edema, collateral superficial veins, prior documented DVT, and an alternative diagnosis that is at least as likely as DVT (which subtracts 2 points). A score of 2 or more designates the patient as "DVT likely," while a score below 2 designates "DVT unlikely."

D-dimer testing is a highly sensitive assay for the presence of cross-linked fibrin degradation products, with sensitivity exceeding 95 to 97% for VTE. However, its low specificity limits its usefulness as a positive diagnostic test. The primary value of D-dimer is in its negative predictive power: a negative D-dimer in a patient with low or intermediate clinical probability effectively excludes DVT. For patients over 50 years of age, the age-adjusted D-dimer cutoff (age multiplied by 10 mcg/L) improves specificity by approximately 10 to 15% without sacrificing sensitivity, reducing unnecessary imaging.

Compression ultrasonography (CUS) is the definitive imaging test for DVT, with non-compressibility of the vein on direct probe pressure being the diagnostic criterion. The sensitivity of CUS exceeds 95% for proximal DVT (involving the popliteal, femoral, or iliac veins) but is lower, approximately 70%, for isolated calf DVT. When clinical suspicion remains high despite a negative initial CUS, serial ultrasonography repeated in 5 to 7 days is recommended to detect propagation of a calf DVT into the proximal venous system.

PE Diagnosis

The diagnostic evaluation of suspected PE follows a similar probabilistic approach using the Wells score for PE, which assigns points for clinical signs of DVT (3 points), PE as the most likely diagnosis (3 points), heart rate above 100 (1.5 points), immobilization or surgery within the past 4 weeks (1.5 points), previous DVT or PE (1.5 points), hemoptysis (1 point), and active malignancy (1 point). A total score of 4 or below designates "PE unlikely," while a score above 4 designates "PE likely."

The PERC (Pulmonary Embolism Rule-Out Criteria) rule provides an additional safety net for patients in the low-risk category. If all eight PERC criteria are negative (age under 50, heart rate below 100, oxygen saturation 95% or above, no hemoptysis, no estrogen use, no prior DVT or PE, no unilateral leg swelling, and no recent surgery or trauma), PE can be excluded without further testing, including D-dimer. This rule was validated to reduce unnecessary testing in emergency department settings where the pretest probability is genuinely low.

For patients with an unlikely Wells score who do not meet PERC criteria, a D-dimer test should be obtained. A negative D-dimer (using an age-adjusted cutoff for patients over 50) effectively excludes PE. A positive D-dimer, or a Wells score indicating PE is likely, should prompt definitive imaging. CT pulmonary angiography (CTPA) is the diagnostic standard, with sensitivity of 95 to 100% and specificity of 95 to 97% for PE. Ventilation-perfusion (V/Q) scanning is an appropriate alternative when CTPA is contraindicated due to contrast allergy, renal insufficiency, or pregnancy, and performs best when the chest radiograph is normal. Lower extremity compression ultrasonography can serve as an adjunct: a positive DVT study in a patient with symptoms suggestive of PE is sufficient to initiate treatment without further imaging. In hemodynamically unstable patients for whom transport to the CT scanner is unsafe, bedside echocardiography demonstrating right ventricular dilation and dysfunction can support the diagnosis and guide emergent therapeutic decisions.

<image>A clinical decision algorithm for PE diagnosis integrating pre-test probability, PERC rule, D-dimer, and imaging. Start with "Suspected PE." First step: assess pre-test probability using Wells score. If Wells ≤4 (PE unlikely): apply PERC rule. If ALL PERC criteria met: PE excluded, no further testing. If PERC not met: obtain D-dimer (use age-adjusted cutoff for >50 years). If D-dimer negative: PE excluded. If D-dimer positive: proceed to CTPA. If Wells >4 (PE likely): proceed directly to CTPA (skip D-dimer). Show CTPA results: positive → treat PE; negative → PE excluded (or consider alternative if high clinical suspicion). Include a separate pathway for hemodynamically unstable patients: bedside echo (RV dilation) → if positive, empiric anticoagulation ± systemic thrombolysis → confirm with CTPA when stable. Show sensitivity/specificity values at each decision point. Clean clinical algorithm with color-coded risk pathways.</image>

Treatment - Anticoagulation

Initial Anticoagulation

Anticoagulation should be initiated as soon as VTE is diagnosed, or even when it is strongly suspected while confirmatory imaging is awaited, provided the bleeding risk is acceptable. Direct oral anticoagulants (DOACs) are preferred over traditional heparin-to-warfarin therapy for most patients based on their comparable efficacy, superior safety profile (particularly lower intracranial hemorrhage rates), fixed dosing, and lack of routine monitoring requirements.

Rivaroxaban and apixaban offer the advantage of a single-drug approach that does not require an initial period of parenteral anticoagulation. Rivaroxaban is initiated at 15 mg twice daily for 21 days followed by 20 mg once daily, as established in the EINSTEIN trials. Apixaban is initiated at 10 mg twice daily for 7 days followed by 5 mg twice daily, as established in the AMPLIFY trial. Edoxaban at 60 mg once daily and dabigatran at 150 mg twice daily both require an initial period of at least 5 days of parenteral heparin therapy before transitioning to oral dosing, as demonstrated in the HOKUSAI-VTE and RE-COVER trials, respectively.

For patients in whom DOACs are not appropriate, the traditional approach of LMWH or fondaparinux bridging to warfarin remains a valid alternative. Enoxaparin at 1 mg/kg twice daily or 1.5 mg/kg once daily, or dalteparin at 200 IU/kg once daily, is initiated concurrently with warfarin, and the overlap is maintained for a minimum of 5 days and until the INR has been at or above 2.0 for at least 24 hours. Unfractionated heparin (UFH), administered as an 80 IU/kg bolus followed by an infusion of 18 IU/kg per hour titrated to an aPTT of 1.5 to 2.5 times control or an anti-Xa level of 0.3 to 0.7 IU/mL, is reserved for specific situations including massive PE where thrombolysis may be needed, severe renal impairment with a creatinine clearance below 30 mL/min, and patients who may require urgent surgical procedures.

Cancer-Associated VTE

The treatment of cancer-associated VTE has evolved considerably. DOACs are now preferred over LMWH for most cancer patients based on the results of several pivotal trials, including the Caravaggio trial (apixaban), SELECT-D (rivaroxaban), and ADAM VTE trial. An important exception exists for patients with gastrointestinal or genitourinary malignancies, in whom rivaroxaban and edoxaban were associated with higher rates of gastrointestinal bleeding. Apixaban appears to have a more favorable safety profile in this subgroup and may be the preferred DOAC. LMWH (dalteparin or enoxaparin) remains the preferred choice for cancer patients with high gastrointestinal or genitourinary bleeding risk, significant drug interactions with DOACs, or concerns about gastrointestinal absorption due to mucositis or obstruction. The minimum duration of anticoagulation for cancer-associated VTE is 6 months, and treatment should generally be continued indefinitely while the cancer remains active or the patient continues to receive anticancer therapy.

Duration of Anticoagulation

The duration of anticoagulation following VTE is one of the most important clinical decisions in thrombosis medicine and is determined primarily by the nature of the provoking factor, the risk of recurrence, and the individual patient's bleeding risk. VTE provoked by a major transient risk factor requires 3 months of anticoagulation. VTE provoked by a minor transient risk factor is treated for 3 to 6 months, with extended therapy considered if additional persistent risk factors are present. Unprovoked VTE requires a minimum of 3 months of anticoagulation, after which the clinician must weigh the benefits of extended therapy against the ongoing bleeding risk.

Extended anticoagulation reduces VTE recurrence by 80 to 90% but imposes a persistent annual bleeding risk that does not diminish over time. The decision to extend therapy is individualized based on multiple factors including formal bleeding risk assessment (using tools such as the HAS-BLED or VTE-BLEED scores), the D-dimer level measured 1 month after stopping anticoagulation (elevated D-dimer predicts higher recurrence), patient sex (males have a higher recurrence risk than females with provoked VTE), the initial clot burden, and patient preference. Importantly, the availability of reduced-dose extended therapy regimens has changed the risk-benefit calculation substantially. Apixaban at 2.5 mg twice daily (AMPLIFY-EXT trial) and rivaroxaban at 10 mg daily (EINSTEIN CHOICE trial) both demonstrated effective extended prevention with bleeding rates comparable to aspirin, making extended anticoagulation a more attractive option for patients with unprovoked VTE.

Submassive and Massive PE

Risk Stratification

Risk stratification of acute PE is essential for determining the appropriate level of care and therapeutic intensity. Low-risk PE is defined by normal hemodynamics, absence of right ventricular dysfunction, and normal cardiac biomarkers. These patients can be safely treated as outpatients if they meet validated criteria (Hestia criteria or simplified PESI score of 0) and have adequate follow-up arrangements.

Submassive (intermediate-risk) PE is characterized by preserved systemic blood pressure but evidence of right ventricular dysfunction on echocardiography or CT angiography, with or without elevation of cardiac biomarkers (troponin, BNP). These patients require hospitalization with close monitoring. Systemic thrombolysis is not routinely recommended for submassive PE based on the PEITHO trial, which demonstrated that alteplase reduced hemodynamic decompensation but at the cost of increased intracranial hemorrhage without a mortality benefit. Catheter-directed therapy (CDT), which delivers lower doses of thrombolytics directly into the pulmonary arterial clot, is an area of active investigation with promising early data from the ULTIMA and SEATTLE II trials but is not yet established as standard of care. Patients with submassive PE should be monitored in an ICU or step-down unit with escalation to rescue thrombolysis or catheter-directed therapy if hemodynamic deterioration occurs.

Massive (high-risk) PE is defined by hemodynamic instability, including systolic blood pressure below 90 mmHg sustained for more than 15 minutes, requirement for vasopressor support, or cardiac arrest. Systemic thrombolysis is the first-line treatment, with alteplase administered at 100 mg intravenously over 2 hours for hemodynamically unstable patients or 0.6 mg/kg (maximum 50 mg) over 15 minutes in the setting of cardiac arrest. Surgical pulmonary embolectomy is indicated when thrombolysis is contraindicated or has failed. Catheter-directed therapy represents an alternative to surgical embolectomy at centers with the requisite expertise. Extracorporeal membrane oxygenation (ECMO) can serve as a bridge to definitive therapy in patients with refractory cardiogenic shock or cardiac arrest.

IVC Filter Indications

Inferior vena cava (IVC) filters are indicated exclusively for patients with acute proximal DVT or PE who have an absolute contraindication to anticoagulation. Retrievable filters are strongly preferred over permanent filters, and the filter should be removed as soon as anticoagulation can be safely initiated. The routine placement of IVC filters in addition to anticoagulation is not supported by evidence: the PREPIC2 trial demonstrated no benefit from prophylactic filter placement alongside anticoagulation and showed an increased risk of subsequent DVT in the filter group.

Post-Thrombotic Syndrome (PTS)

Post-thrombotic syndrome develops in 20 to 50% of patients following DVT despite adequate anticoagulation and represents the most common long-term complication of DVT. It manifests as chronic venous insufficiency with symptoms including leg pain, swelling, heaviness, skin hyperpigmentation, lipodermatosclerosis, and in severe cases, venous ulceration. The pathogenesis involves a combination of residual venous obstruction, valvular incompetence from thrombus-mediated valve damage, and chronic venous hypertension. Risk factors for developing PTS include proximal DVT (particularly iliofemoral), recurrent ipsilateral DVT, obesity, and inadequate anticoagulation during the acute treatment period. Prevention strategies include early mobilization and adequate anticoagulation. The role of graduated compression stockings has been debated: the SOX trial demonstrated no benefit of routine compression stocking use for PTS prevention, though many experts continue to recommend them for symptomatic relief.

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Chronic thromboembolic pulmonary hypertension develops in 2 to 4% of patients following acute PE and results from the organization and fibrosis of residual thrombi within the pulmonary vasculature, leading to progressive vascular remodeling and increased pulmonary vascular resistance. The disorder should be suspected in any patient who reports persistent dyspnea after an episode of PE despite adequate anticoagulation. The V/Q scan is the preferred screening test for CTEPH, as it is more sensitive than CTPA for detecting the pattern of mismatched perfusion defects characteristic of this condition. The diagnosis is confirmed by right heart catheterization demonstrating a mean pulmonary arterial pressure of 20 mmHg or greater in the presence of organized thromboembolic disease on imaging.

Treatment of CTEPH involves lifelong anticoagulation for all patients. Pulmonary endarterectomy (PEA) is the definitive and potentially curative intervention for patients with surgically accessible central disease and is performed at specialized centers with demonstrated expertise. Balloon pulmonary angioplasty (BPA) has emerged as an effective alternative for patients with predominantly distal disease who are not candidates for PEA. Riociguat, a soluble guanylate cyclase stimulator, is the pharmacologic treatment of choice for patients with inoperable CTEPH or persistent pulmonary hypertension following PEA.

Key Clinical Pearls

• DOACs (rivaroxaban and apixaban as single-drug approach) are first-line for most VTE; they are simpler, safer, and do not require INR monitoring
• Age-adjusted D-dimer (age x 10 for patients >50) improves specificity and reduces unnecessary imaging by 10-15% in older patients
• Apixaban 2.5 mg BID or rivaroxaban 10 mg daily provides effective extended VTE prevention with lower bleeding risk than full-dose anticoagulation; offer to patients with unprovoked VTE
• For cancer-associated VTE, apixaban is preferred among DOACs for patients with GI/GU malignancy (lower GI bleeding risk than rivaroxaban/edoxaban)
• Systemic thrombolysis for PE is reserved for massive PE with hemodynamic instability; it is NOT indicated for submassive PE based on PEITHO (increased ICH without survival benefit)
• CTEPH should be considered in any patient with persistent dyspnea after PE; V/Q scan is the screening test of choice (CTPA may miss CTEPH)

References

1. Kearon C, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352.
2. Konstantinides SV, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603.
3. Agnelli G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer (Caravaggio). N Engl J Med. 2020;382(17):1599-1607.
4. Meyer G, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism (PEITHO). N Engl J Med. 2014;370(15):1402-1411.
5. Weitz JI, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism (EINSTEIN CHOICE). N Engl J Med. 2017;376(13):1211-1222.

Read this lecture as Markdown